ライフサイエンスコーパス: noninvasive testing

1 suspected coronary artery disease requiring noninvasive testing.

2 n quality of life than evaluation with usual noninvasive testing.

3 sis of heart failure cannot be determined by noninvasive testing.

4 heterization recommend a risk assessment and noninvasive testing.

5 emia, even in patients selected for abnormal noninvasive testing.

6 icity of symptoms and diagnostic accuracy of noninvasive testing.

7 es appear to obviate the need for subsequent noninvasive testing.

8 e, and extent of atherosclerosis detected by noninvasive testing.

9 cted coronary artery disease (CAD) requiring noninvasive testing.

10 nd 35.1% in 2014), and high-risk findings on noninvasive testing (22.2% in 2010 and 33.2% in 2014) (P

11 tic patients with suspected CAD who required noninvasive testing, a strategy of initial CTA, as compa

12 Based on the noninvasive testing alone, 27% patients underwent surger

13 icant cardioprotective effect as measured by noninvasive testing and clinical CHF.

14 Noninvasive testing and left ventricular ejection fracti

15 tients or patients with low-risk findings on noninvasive testing and minimal medical therapy are view

16 tients or patients with low-risk findings on noninvasive testing and minimal medical therapy were vie

17 exclusively among subjects first undergoing noninvasive testing and overall, was performed in only 1

18 ces and time trends in patients referred for noninvasive testing and subsequent use of invasive proce

19 We determined patterns of noninvasive testing and the diagnostic yield of catheter

20 afe omission of the intensive care phase and noninvasive testing, and a day 3 hospital discharge stra

21 f medical therapy, risk level as assessed by noninvasive testing, and coronary anatomy.

22 f medical therapy, risk level as assessed by noninvasive testing, and coronary anatomy.

23 plaque composition and behavior, accuracy of noninvasive testing, and response to surgical and percut

24 on of coronary calcium by EBCT as an initial noninvasive testing approach minimized direct costs, and

25 catheterization and revascularization after noninvasive testing are not well defined.

26 t known coronary artery disease referred for noninvasive testing at 193 sites in North America.

27 essment with right heart catheterization and noninvasive testing at 3 to 6 months and annually therea

28 nosis in symptomatic patients often involves noninvasive testing before invasive coronary angiography

29 Noninvasive testing can help identify liver disease in s

30 At present, the choice of noninvasive testing for a diagnosis of significant coron

31 he preceding year, who received nonemergent, noninvasive testing for CAD (n = 282,830).

32 Initial noninvasive testing for H. pylori has lower charges than

33 Noninvasive testing for Helicobacter pylori is widely av

34 y with biopsy should be performed only after noninvasive testing for infectious diarrhea and a thorou

35 Guidelines recommend noninvasive testing for patients with stable chest pain,

36 the practicing clinician in the selection of noninvasive testing for stable chest pain.

37 perfusion therapy, risk level as assessed by noninvasive testing, fractional flow reserve testing, an

38 Overall, noninvasive testing had only a modest impact on clinical

39 A hallmark of noninvasive testing has been the identification of patie

40 However, the role of noninvasive testing has recently been challenged.

41 ce of compelling clinical evidence and after noninvasive testing has yielded negative findings.

42 Cardiac magnetic resonance (CMR), noninvasive testing, has been used in monitoring heart t

43 Results of prospectively acquired noninvasive testing in 47 consecutive transplant recipie

44 downstream use of invasive procedures after noninvasive testing in community practice.

45 Further use of noninvasive testing, invasive procedures, medications, a

46 Noninvasive testing is best done in selected patients wh

47 Therefore, noninvasive testing is recommended by relevant guideline

48 The most important goal of noninvasive testing is to identify patients with left ma

49 use of coronary angiography without previous noninvasive testing is typically not advocated.

50 guidelines when demonstration of ischemia by noninvasive testing is unavailable.

51 egnant population in person with a rapid and noninvasive testing method may provide a practical model

52 rmation in combination with more traditional noninvasive testing methods.

53 re unit and day 3 hospital discharge without noninvasive testing [n = 237] or traditional care [n = 2

54 Limited data exist on how noninvasive testing options compare for evaluating patie

55 st regarding the need for intensive care and noninvasive testing or the appropriate length of hospita

56 d positive predictive values to conventional noninvasive testing pathways across all prevalence subgr

57 ase do not have documentation of ischemia by noninvasive testing prior to elective PCI.

58 role of screening with serum biomarkers and noninvasive testing remains controversial, and in this r

59 Coronary angiography without previous noninvasive testing resulted in reasonable cost-effectiv

60 Noninvasive testing should improve accuracy in decision

61 Thus, no currently available noninvasive testing strategy can reliably exclude DVT in

62 treadmill testing may emerge as the initial noninvasive testing strategy in elderly patients who are

63 ease in women, there is a need to identify a noninvasive testing strategy that is able to accurately

64 19 vs. $ 10,734; p < 0.0001), whereas in the noninvasive testing stratum, when the cost weight of FFR

65 to evaluate the prognostic value of routine noninvasive testing--stress thallium-201 imaging, rest t

66 spected coronary artery disease who required noninvasive testing, symptoms and QOL improved significa

67 This noninvasive testing technique is a valid indicator of po

68 ice the rate in the community; one-third had noninvasive testing that indicated advanced fibrosis or

69 Because patients may have had abnormal noninvasive testing that led to performance of coronary

70 NS: Among contemporary patients referred for noninvasive testing, the DF risk score overestimates the

71 l lung diseases provides the opportunity for noninvasive testing to establish an etiologic diagnosis,

72 he choice of either anatomical or functional noninvasive testing to evaluate suspected coronary arter

73 The decision about whether to obtain noninvasive testing to further define cardiovascular sta

74 Noninvasive testing using resting and posttreadmill exer

75 Noninvasive testing was infrequent and medical costs wer

76 Noninvasive testing was performed in 83.9% of the patien

77 history taking and physical examination and noninvasive testing were compared with screening recomme

78 isk factors, and symptoms and the results of noninvasive testing were correlated with the presence of

79 patients with stable chest pain referred for noninvasive testing will have normal coronary arteries a

80 e it may overcome some of the limitations of noninvasive testing, will clearly define high-risk patie

81 old, the most cost-effective option would be noninvasive testing with magnetic resonance elastography

82 servative, ischemia-guided strategy included noninvasive testing with radionuclide ventriculography a

83 " management, defined as medical therapy and noninvasive testing, with subsequent invasive management